Article

The S100A6 calcium-binding protein regulates endothelial cell cycle progression and senescence.

Endothelial Cell Biology Unit, School of Molecular & Cellular Biology, LIGHT Laboratories, University of Leeds, Clarendon Way, Leeds, LS2 9JT, UK.
FEBS Journal (Impact Factor: 3.99). 10/2012; DOI: 10.1111/febs.12044
Source: PubMed

ABSTRACT Endothelial cells regulate many aspects of vascular physiology including vasculogenesis and angiogenesis. The S100 family of calcium-binding protein regulates many aspects of cell function but their roles in vascular physiology are less well understood. Herein, we investigated the expression and function of S100-related family members in endothelial cells. Analysis of total endothelial mRNAs using a human gene chip array revealed significant gene expression of the S100 calcium-binding protein family members S100A6, S100A10, S100A11 and S100A13. We examined the expression and functional properties of the major S100 family member, S100A6, in vascular endothelial cells. Comparison of primary and transformed human cells revealed significant differences in S100A6 protein levels. In primary human endothelial cells, S100A6 was present in both the nucleus and cytoplasm. To assess the function of endothelial S100A6, we depleted protein levels using RNA interference and this caused increased cell cycle arrest in the G2/M phase under different conditions. S100A6 depletion caused a decrease in both CDK1 and phospho-CDK1 levels which are essential for eukaryote cell cycle progression. S100A6 depletion also decreased CDK1, cyclin A1 and cyclin B gene expression with effects on cell cycle progression. Depletion of endothelial S100A6 levels also elevated β-galactosidase expression which is an important hallmark of cellular senescence and exit from the mammalian cell cycle. We thus propose that S100A6 has an important role in regulating endothelial commitment to and progression through the cell cycle. © 2012 The Authors Journal compilation © 2012 FEBS.

0 Bookmarks
 · 
119 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: S100A6 is a calcium binding protein that, like some other members of the S100 protein family, is able to bind p53. This interaction may be physiologically relevant considering the numerous connotations of S100 proteins, and of S100A6 in particular, with cancer and metastasis. In this work we show that the interaction with S100A6 is limited to unmodified or phoshorylated p53 and is inhibited by p53 acetylation. Using in vitro acetylation assay we show that the presence of S100A6 attenuates p53 acetylation by p300. Furthermore, using ELISA, we show that S100A6 and the TAZ2 domain of p300 bind p53 with similar affinities and that S100A6 effectively competes with TAZ2 for binding to p53. Our results add another element to the complicated scheme of p53 activation.
    Journal of Molecular Biology 06/2013; · 3.91 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Papillary thyroid carcinoma (PTC) exhibits various molecular abnormalities, both when sporadic and radiation-related. PTC is still diagnosed in adult individuals who were younger than 18 years at the time of the Chornobyl accident in 1986 and lived within the contaminated area. The preoperative diagnosis of PTC is based on ultrasound-guided fine needle aspiration cytology (FNAC), which is highly informative in up to 90% of biopsies. FNAC is not informative for the discrimination of follicular thyroid carcinoma (FTC) from follicular thyroid adenoma (FTA). Moreover, FNAC is often unreliable for diagnosis of cystic PTC due to its common presentation as a mural nodule in a cystic mass. In case of cystic PTC, biopsy sometimes reveals a cystic fluid containing insufficient amount of representative cells for cytology. In this work, PTC was characterized in relation to irradiation from radioactivity at childhood. Possible preoperative diagnostic markers for discrimination between PTC and other follicular thyroid neoplasms were identified, and their validity was tested. In Study I molecular, genetic and clinical characteristics in 70 post-Chornobyl PTCs were investigated. A common BRAF 1799T>A mutation was detected in 26 cases, overrepresentation of RET/PTC1 in 20 whereas RET/PTC3 was found in 4 cases. BRAF mutation was observed 3.5 times less frequent in the PTC accompanied by chronic lymphocytic thyroiditis (PTC/CLT) as compared to PTC only (12% vs. 44%). Greater expression of cyclin A was observed in PTC ≥ 2 cm as compared to PTC < 2 cm (1.2% vs. 0.6%). In conclusion, BRAF mutation and RET/PTC1 rearrangement as well as other molecular features of adult post-Chornobyl PTC were partly overlapping with other reported PTC cohorts. In Study II the SELDI-TOF mass spectrometry method was applied for PTC, FTC, FTA and normal thyroid tissue (NT). Significant overexpression of the protein S100A6 was identified in PTC as compared to FTC, FTA and NT (p < 0.05). This result was verified both by Western blot (WB), using the same samples, and by IHC in these and additionally in the PTC samples investigated in Study I. Moreover, the presence of two post-translational modifications of S100A6 was observed and verified by LC-MS/MS. S100A6 expression is strongly associated with PTC, and can therefore be tested for discrimination between follicular thyroid tumors and PTC. In Study III a two dimensional gel electrophoresis followed by MALDI-TOF mass spectrometry for proteomic profiling of PTC, FTC and FTA was performed. 25 protein spots showing significantly different expression between studied groups were identified. Of these, 9 protein spots were selected for further analyses by WB using the initially studied samples and by IHC using these as well as samples from Study I. The findings suggest additional proteins to be deregulated in thyroid tumors, and their clinical significance can now be further studied. In Study IV preoperative diagnostic markers for PTC in cystic lesions were identified by applying LC-MS/MS method. Out of all 1581 identified proteins, annexin A3 (ANXA3), carboxymethylenebutenolidase homolog (CMBL) cytokeratin 19 (CK-19) and S100A13 were selected for validation by IHC and WB. ANXA3 and CMBL showed overexpression in both controls and PTCs, whereas S100A13 and CK-19 were up-regulated in PTC only (p < 0.05), suggesting their possible role for discrimination between cystic PTC and benign thyroid cysts.
    09/2013, Degree: PhD, Supervisor: Jan Zedenius
  • [Show abstract] [Hide abstract]
    ABSTRACT: S100 protein family has been implicated in multiple stages of tumorigenesis and progression. Among the S100 genes, 22 are clustered at chromosome locus 1q21, a region frequently rearranged in cancers. S100 protein possesses a wide range of intracellular and extracellular functions such as regulation of calcium homeostasis, cell proliferation, apoptosis, cell invasion and motility, cytoskeleton interactions, protein phosphorylation, regulation of transcriptional factors, autoimmunity, chemotaxis, inflammation and pluripotency. Many lines of evidence suggest that altered expression of S100 proteins was associated with tumor progression and prognosis. Therefore, S100 proteins might also represent potential tumor biomarkers and therapeutic targets. In this review, we summarize the evidence connecting S100 protein family and cancer and discuss the mechanisms by which S100 exerts its diverse functions.
    American Journal of Cancer Research 01/2014; 4(2):89-115. · 3.97 Impact Factor

Full-text (2 Sources)

Download
7 Downloads
Available from
Dec 18, 2014